Irreversible alterations such as B2M mutations and HLA class I loss of heterozygosity (LOH) are frequently observed in melanoma, lung cancer, and microsatellite instability–high colorectal cancer, particularly in tumours that relapse after immune checkpoint blockade.81, 82. This evidence concerns the gene B2M and lung cancer.